## Julian P Halcox

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/921761/publications.pdf

Version: 2024-02-01

118 papers 19,961 citations

43 h-index 22166 113 g-index

124 all docs

124 docs citations

times ranked

124

23068 citing authors

#	Article	IF	CITATIONS
1	Achievement of European Society of Cardiology/European Atherosclerosis Society lipid targets in very high-risk patients: Influence of depression and sex. PLoS ONE, 2022, 17, e0264529.	2.5	1
2	Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study. European Journal of Preventive Cardiology, 2021, 28, 854-861.	1.8	14
3	An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS). European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 40-49.	3.0	9
4	Response: Letter to the editor. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e27-e28.	3.0	0
5	Single-lead ECGs (AliveCor) are a feasible, cost-effective and safer alternative to 12-lead ECGs in community diagnosis and monitoring of atrial fibrillation. BMJ Open Quality, 2021, 10, e001270.	1.1	1
6	<scp>Glucagonâ€like peptideâ€l receptor agonists</scp> improve biomarkers of inflammation and oxidative stress: A systematic review and metaâ€analysis of randomised controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 1806-1822.	4.4	53
7	Acute effect of a single session of lipoprotein apheresis on central haemodynamics in patients with familial hypercholesterolaemia. Atherosclerosis, 2021, 325, 121-123.	0.8	0
8	Epilepsy, antiepileptic drugs, and the risk of major cardiovascular events. Epilepsia, 2021, 62, 1604-1616.	5.1	27
9	Influence of Maternal Lifestyle and Diet on Perinatal DNA Methylation Signatures Associated With Childhood Arterial Stiffness at 8 to 9 Years. Hypertension, 2021, 78, 787-800.	2.7	10
10	The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis. Rheumatology, 2021, 60, 2852-2861.	1.9	9
11	Associations of depression-anxiety and dyslipidaemia with subclinical carotid arterial disease: Findings from the Whitehall II Study. European Journal of Preventive Cardiology, 2020, 27, 800-807.	1.8	6
12	Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015. European Heart Journal, 2020, 41, 1636-1649.	2.2	36
13	Active Children Through Individual Vouchers Evaluation: A Mixed-Method RCT. American Journal of Preventive Medicine, 2020, 58, 232-243.	3.0	12
14	Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK. Atherosclerosis, 2020, 313, 126-136.	0.8	52
15	Diagnostic performance of virtual fractional flow reserve derived from routine coronary angiography using segmentation free reduced order (1-dimensional) flow modelling. JRSM Cardiovascular Disease, 2020, 9, 204800402096757.	0.7	2
16	HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis, 2019, 291, 62-70.	0.8	142
17	What works best when implementing a physical activity intervention for teenagers? Reflections from the ACTIVE Project: a qualitative study. BMJ Open, 2019, 9, e025618.	1.9	3
18	Chronic kidney disease, cardiovascular risk markers and total mortality in older men: cystatin C versus creatinine. Journal of Epidemiology and Community Health, 2019, 73, 645-651.	3.7	10

#	Article	IF	Citations
19	Carotid artery wave intensity in mid- to late-life predicts cognitive decline: the Whitehall II study. European Heart Journal, 2019, 40, 2300-2309.	2.2	57
20	Predictors of cardiovascular health in teenagers (aged 13–14 years): a cross-sectional study linked with routine data. Open Heart, 2019, 6, e001147.	2.3	1
21	Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study. International Journal of Cardiology, 2018, 253, 167-173.	1.7	47
22	Ready-to-use food supplement, with or without arginine and citrulline, with daily chloroquine in Tanzanian children with sickle-cell disease: a double-blind, random order crossover trial. Lancet Haematology,the, 2018, 5, e147-e160.	4.6	17
23	Risk classification in primary prevention of CVD according to QRISK2 and JBS3 †heart age', and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study. Open Heart, 2018, 5, e000849.	2.3	23
24	GWAS and colocalization analyses implicate carotid intima-media thickness and carotid plaque loci in cardiovascular outcomes. Nature Communications, 2018, 9, 5141.	12.8	119
25	A genetic programming approach to development of clinical prediction models: A case study in symptomatic cardiovascular disease. PLoS ONE, 2018, 13, e0202685.	2.5	7
26	Response by Halcox and Wareham to Letter Regarding Article, "Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study― Circulation, 2018, 137, 2193-2194.	1.6	3
27	Active children through individual vouchers – evaluation (ACTIVE): protocol for a mixed method randomised control trial to increase physical activity levels in teenagers. BMC Public Health, 2018, 18, 7.	2.9	7
28	Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. BMJ Open, 2017, 7, e013398.	1.9	22
29	Guidelines for type 2 diabetes: keeping a finger on the pulse. Lancet Diabetes and Endocrinology,the, 2017, 5, 420.	11.4	1
30	Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. BMJ Open, 2017, 7, e015363.	1.9	38
31	Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation. Circulation, 2017, 136, 1784-1794.	1.6	434
32	Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes. Atherosclerosis, 2017, 264, 36-43.	0.8	16
33	Self-reported sleep duration and napping, cardiac risk factors and markers of subclinical vascular disease: cross-sectional study in older men. BMJ Open, 2017, 7, e016396.	1.9	20
34	Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovascular Disorders, 2017, 17, 160.	1.7	80
35	Increased fibrinogen responses to psychophysiological stress predict future endothelial dysfunction implications for cardiovascular disease?. Brain, Behavior, and Immunity, 2017, 60, 233-239.	4.1	12
36	Arterial pathophysiology and comparison of two devices for pulse wave velocity assessment in elderly men: the British regional heart study. Open Heart, 2017, 4, e000645.	2.3	6

#	Article	IF	CITATIONS
37	HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis, 2016, 255, 128-139.	0.8	76
38	The association between blood pressure and lipid levels in Europe. Journal of Hypertension, 2016, 34, 2155-2163.	0.5	21
39	Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. International Journal of Cardiology, 2016, 218, 83-88.	1.7	76
40	Objectively measured physical activity, sedentary time and subclinical vascular disease: Cross-sectional study in older British men. Preventive Medicine, 2016, 89, 194-199.	3.4	47
41	Objectively measured physical activity and sedentary behaviour and ankle brachial index: Cross-sectional and longitudinal associations in older men. Atherosclerosis, 2016, 247, 28-34.	0.8	30
42	Validation of a new method for non-invasive assessment of vasomotor function. European Journal of Preventive Cardiology, 2016, 23, 577-583.	1.8	20
43	Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?. Metabolic Syndrome and Related Disorders, 2015, 13, 1-21.	1.3	26
44	Reclassification of European patients' cardiovascular risk using the updated Systematic Coronary Risk Evaluation algorithm. European Journal of Preventive Cardiology, 2015, 22, 200-202.	1.8	8
45	Low Rates of Both Lipid-Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe. PLoS ONE, 2015, 10, e0115270.	2.5	25
46	Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk. Human Reproduction, 2014, 29, 2041-2049.	0.9	24
47	Higher systolic blood pressure with normal vascular function measurements in pretermâ€born children. Acta Paediatrica, International Journal of Paediatrics, 2014, 103, 904-912.	1.5	26
48	Improving diagnosis and treatment of women with angina pectoris and microvascular disease: The iPOWER study design and rationale. American Heart Journal, 2014, 167, 452-458.	2.7	44
49	Networks for improving care in patients with acute coronary syndrome: A framework. Acute Cardiac Care, 2014, 16, 41-48.	0.2	2
50	Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, nonâ€diabetic controls. Diabetes, Obesity and Metabolism, 2014, 16, 1165-1173.	4.4	286
51	Lipid-lowering therapy and mortality post-MI: is it just about the LDL?. Heart, 2014, 100, 825-826.	2.9	0
52	C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMC Cardiovascular Disorders, 2014, 14, 25.	1.7	40
53	Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. Clinical Lipidology, 2013, 8, 329-344.	0.4	5
54	Low-Dose Sodium Nitrite Attenuates Myocardial Ischemia and Vascular Ischemia-Reperfusion Injury in Human Models. Journal of the American College of Cardiology, 2013, 61, 2534-2541.	2.8	52

#	Article	IF	CITATIONS
55	Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. International Journal of Cardiology, 2013, 166, 210-214.	1.7	12
56	Omega-3 Fatty Acids and Mortality Outcome in Patients With and Without Type 2 Diabetes After Myocardial Infarction: A Retrospective, Matched-Cohort Study. Clinical Therapeutics, 2013, 35, 40-51.	2.5	34
57	The development and validation of the major life changing decision profile (MLCDP). Health and Quality of Life Outcomes, 2013, 11, 78.	2.4	13
58	Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. European Journal of Preventive Cardiology, 2012, 19, 541-550.	1.8	92
59	Levels of circulating endothelial cells and colony-forming units are influenced by age and dyslipidemia. Pediatric Research, 2012, 72, 299-304.	2.3	13
60	Defining the Role of Lipoprotein Apheresis in the Management of Familial Hypercholesterolemia. American Journal of Cardiovascular Drugs, 2011, 11, 363-370.	2.2	25
61	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	2.2	2,767
62	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 1-44.	0.8	180
63	ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis, 2011, 217, 3-46.	0.8	561
64	Direct Vasoactive Properties of Thienopyridine-Derived Nitrosothiols. Journal of Cardiovascular Pharmacology, 2011, 58, 550-558.	1.9	9
65	Extended extraocular phenotype of PROM1 mutation in kindreds with known autosomal dominant macular dystrophy. European Journal of Human Genetics, 2011, 19, 131-137.	2.8	24
66	Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study. BMC Public Health, 2011, 11, 704.	2.9	28
67	Prevalence and Predictors of Carotid Wall Triple Line Pattern in a General Population Sample. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1682-1688.	2.4	6
68	Letter by Halcox Regarding Article, "OMEGA, A Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction― Circulation, 2011, 124, e21; author reply e24-5.	1.6	4
69	The Arterial Pulse: Vascular Biology, Vascular Function Testing, and Therapies. Cardiology Research and Practice, 2011, 2011, 1-2.	1.1	1
70	Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. European Heart Journal, 2011, 32, 2143-2152.	2,2	285
71	Where Are We Heading with Noninvasive Clinical Vascular Physiology? Why and How Should We Assess Endothelial Function?. Cardiology Research and Practice, 2011, 2011, 1-9.	1.1	14
72	Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). BMC Public Health, 2010, 10, 382.	2.9	22

#	Article	IF	Citations
73	Determinants of vascular phenotype in a large childhood population: the Avon Longitudinal Study of Parents and Children (ALSPAC). European Heart Journal, 2010, 31, 1502-1510.	2.2	65
74	Endothelial response to childhood infection: The role of mannose-binding lectin (MBL). Atherosclerosis, 2010, 208, 217-221.	0.8	14
75	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	2.2	2,649
76	Niacin Compared with Ezetimibe. New England Journal of Medicine, 2010, 362, 1046-1048.	27.0	10
77	Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training: Key components of the position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. European Heart Journal, 2010, 31. 1967-1974.	2.2	306
78	Clinical approaches to assess endothelial function in vivo. , 2010, , 201-217.		0
79	Cardiovascular Risk Factors in Infancy and Childhood. , 2010, , 1219-1227.		0
80	Endothelial Function Predicts Progression of Carotid Intima-Media Thickness. Circulation, 2009, 119, 1005-1012.	1.6	281
81	Vascular impact of progenitor cell mobilisation for cardiac repair post-myocardial infarction. Heart, 2009, 95, 1301-1302.	2.9	1
82	Increased Arterial Stiffness in HIV-Infected Children: Risk Factors and Antiretroviral Therapy. Antiviral Therapy, 2009, 14, 1075-1079.	1.0	45
83	PDE5 inhibitors and pulmonary hypertension. Current Sexual Health Reports, 2008, 5, 171-178.	0.8	0
84	Dilatation in the femoral vascular bed does not cause retrograde relaxation of the iliac artery in the anaesthetized pig. Acta Physiologica, 2008, 194, 175-175.	3.8	0
85	Quantitative detection of circulating endothelial cells in vasculitis: comparison of flow cytometry and immunomagnetic bead extraction. Journal of Thrombosis and Haemostasis, 2008, 6, 1025-1032.	3.8	36
86	Systemic Vascular Endothelial Dysfunction in Peyronie's Disease. Journal of Sexual Medicine, 2008, 5, 2688-2693.	0.6	16
87	Methodological Approaches to Optimize Reproducibility and Power in Clinical Studies of Flow-Mediated Dilation. Journal of the American College of Cardiology, 2008, 51, 1959-1964.	2.8	183
88	Arterial stiffness and inflammatory response to psychophysiological stress. Brain, Behavior, and Immunity, 2008, 22, 941-948.	4.1	44
89	Socioeconomic status moderates the association between carotid intima-media thickness and cognition in midlife: Evidence from the Whitehall II study. Atherosclerosis, 2008, 197, 541-548.	0.8	32
90	Endothelial Dysfunction and Cytomegalovirus Replication in Pediatric Heart Transplantation. Circulation, 2008, 117, 2657-2661.	1.6	37

#	Article	IF	Citations
91	The relationship between carotid stiffness and circulating levels of heat shock protein 60 in middle-aged men and women. Journal of Hypertension, 2008, 26, 2389-2392.	0.5	16
92	Does High C-reactive Protein Concentration Increase Atherosclerosis? The Whitehall II Study. PLoS ONE, 2008, 3, e3013.	2.5	39
93	Endogenous Endothelin in Human Coronary Vascular Function. Hypertension, 2007, 49, 1134-1141.	2.7	50
94	Stressing the obvious? Cell stress and cell stress proteins in cardiovascular disease. Cardiovascular Research, 2007, 74, 19-28.	3.8	34
95	Childhood origins of arterial disease. Current Opinion in Pediatrics, 2007, 19, 538-545.	2.0	46
96	Endothelial Function and Dysfunction. Circulation, 2007, 115, 1285-1295.	1.6	2,037
97	A dose-response study of hormone replacement in young hypogonadal women: effects on intima media thickness and metabolism. Clinical Endocrinology, 2007, 66, 070302041622001-???.	2.4	65
98	Non-Invasive Assessment of Endothelial Function. Journal of the American College of Cardiology, 2006, 48, 1846-1850.	2.8	116
99	The role of nitric oxide in early atherosclerosis. European Journal of Clinical Pharmacology, 2006, 62, 69-78.	1.9	7
100	The imaging of coronary artery disease. Medicine, 2006, 34, 373-376.	0.4	0
101	Circulating Human Heat Shock Protein 60 in the Blood of Healthy Teenagers: A Novel Determinant of Endothelial Dysfunction and Early Vascular Injury?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e141-2.	2.4	23
102	Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension*. Journal of Hypertension, 2005, 23, 233-246.	0.5	637
103	Endothelial function and dysfunction. Part I. Journal of Hypertension, 2005, 23, 7-17.	0.5	553
104	Endothelial Dysfunction in Childhood Infection. Circulation, 2005, 111, 1660-1665.	1.6	123
105	Vasculopathy in Turner Syndrome: Arterial Dilatation and Intimal Thickening without Endothelial Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5161-5166.	3.6	142
106	Stem cells as future therapy in cardiology. British Journal of Hospital Medicine (London, England:) Tj ETQq0 0 0 rg	zBT/Overlo	ock 10 Tf 50
107	Early Structural and Functional Changes of the Vasculature in HIV-Infected Children. Circulation, 2005, 112, 103-109.	1.6	162
108	A Comparison of Echocardiography and Magnetic Resonance Imaging in Cardiovascular Screening of Adults with Turner Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5966-5971.	3.6	135

#	Article	IF	CITATIONS
109	Beyond the Laboratory: Clinical Implications for Statin Pleiotropy. Circulation, 2004, 109, II-42-II-48.	1.6	161
110	Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk. New England Journal of Medicine, 2003, 348, 593-600.	27.0	3,249
111	Increased Serum Levels of Heat Shock Protein 70 Are Associated With Low Risk of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1055-1059.	2.4	183
112	Predisposition to Atherosclerosis by Infections. Circulation, 2002, 106, 184-190.	1.6	279
113	Prognostic Value of Coronary Vascular Endothelial Dysfunction. Circulation, 2002, 106, 653-658.	1.6	1,293
114	The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. Journal of the American College of Cardiology, 2002, 40, 1232-1240.	2.8	271
115	Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. Journal of the American College of Cardiology, 2001, 38, 1089-1095.	2.8	54
116	Antibodies to Human Heat-Shock Protein 60 Are Associated With the Presence and Severity of Coronary Artery Disease. Circulation, 2001, 103, 1071-1075.	1.6	203
117	Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H2470-H2477.	3.2	95
118	Coronary vascular endothelial function and myocardial ischemia: why should we worry about endothelial dysfunction?. Coronary Artery Disease, 2001, 12, 475-484.	0.7	15